Comparative Pharmacology
Head-to-head clinical analysis: MOUNJARO versus TRULICITY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MOUNJARO versus TRULICITY.
MOUNJARO vs TRULICITY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tirzepatide is a once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It activates GIP and GLP-1 receptors, potentiating glucose-dependent insulin secretion from pancreatic beta cells, reducing glucagon secretion, slowing gastric emptying, and promoting satiety via hypothalamic appetite regulation.
Glucagon-like peptide-1 (GLP-1) receptor agonist. Increases glucose-dependent insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.
Subcutaneous injection once weekly. Starting dose: 2.5 mg for 4 weeks, then increase to 5 mg for at least 4 weeks. For additional glycemic control, may increase in 2.5 mg increments after at least 4 weeks on current dose. Maximum dose: 15 mg once weekly.
1.5 mg subcutaneously once weekly, with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 5 days (range 4-6 days), supporting once-weekly dosing. Achieves steady-state after 4-5 weeks.
Terminal elimination half-life approximately 5 days (112–120 hours) after subcutaneous administration, supporting once-weekly dosing.
Primarily eliminated via proteolytic degradation, with the parent drug not significantly excreted renally or in feces. Small amounts of metabolites may be excreted in urine and feces.
Renal: negligible (intact peptide not excreted in urine); Biliary/fecal: peptide backbone catabolized via proteolysis, with amino acids recycled; no biliary excretion of intact drug.
Category C
Category C
Dual GIP/GLP-1 Receptor Agonist
GLP-1 Receptor Agonist